-
Drovix Launches In-House Multi-Asset Liquidity and Execution Stack for Sub-Millisecond Fills, Tighter Spreads
-
Australia charges man with trying to pass Ukraine military intel to Russia
-
'So bad it's good': rough animated film becomes surprise Chinese hit
-
Ex-Pakistan PM Khan taken back to jail after hospital checks: govt
-
'I'll adapt': First pregnant candidate navigates French presidential race
-
China, Indonesia hold talks on security, defence
-
Hong Kong convicts Tiananmen vigil activists of inciting subversion
-
Train to nowhere? South Korea's lonely push for peace with the North
-
The Hong Kong Tiananmen vigil activists convicted in national security trial
-
Australia's Hussey mulls role with England for Ashes series
-
Eel-powered Japan whizz-kid, 11, chases Asian Games history
-
Indian captain 'scapegoat' in Britain's Russia shadow fleet case, wife says
-
Asian markets extend rally as traders assess US Treasuries pledge
-
Rosenior seeks to match Paris FC's capital ambition as Ligue 1 returns
-
Barcelona enter new era as Flick targets La Liga hat-trick
-
Inter set for Serie A title defence as Milan get Amorim reboot
-
Pogacar favourite for Vuelta with Grand Tour treble in sight
-
'Greatest' Springboks face All Blacks in clash of juggernauts
-
Bangladesh coach Simmons wary of Australia backlash in second Test
-
William and Harry: Britain's warring royal brothers
-
Hong Kong Tiananmen activists to receive national security verdict
-
UN holds second informal poll for next leader
-
Who are the candidates vying to lead the UN?
-
In US mining hub, black lung rates soar
-
Swiatek into Cincinnati semis after Rybakina injury
-
Champions Arsenal embrace being 'hunted' as Premier League returns
-
University suspends academic behind Jason Arday plagiarism charges
-
World No.2 Rybakina retires from Cincinnati clash with Swiatek
-
Key European leaders demand Israel halt West Bank settlement project
-
'I heard you missed me': Melania Trump jokes about month out of spotlight
-
McIlroy bounces back to share BMW Championship lead
-
Amazon Prime Video to invest $2 bn in Latin America productions
-
Cobolli fueled by candy in sweet defeat of Paul
-
Panama Canal to reduce shipping over El Nino-fueled drought
-
Jailed Pakistan ex-PM Khan moved to hospital on court order: party
-
Maradona trial on hold over possible medical evidence mix-up
-
Pogacar eyes 'missing' piece ahead of Vuelta return
-
'Green dilemma': China's solar boom hurt birds, says study
-
US, Canada 'very close' to trade deal, Ottawa says, as details emerge
-
Pegula hangs on to dispatch Anisimova, reach Cincinnati semi-finals
-
Ronaldinho returns in search of 'beautiful' 300th goal
-
US charges woman with IS-inspired plot to blow up New York State Capitol
-
US pushes allies, China to back Trump's economic war on Iran
-
What a record-breaking El Nino could mean for the world
-
Former NBA MVP Harden reportedly set to return to Cavaliers
-
Duplantis edges Karalis to win Lausanne Diamond League pole vault
-
Brook makes Pakistan pay for drop as England dominate first Test
-
Alcaraz to return for US Open title defence
-
MemeCore Arrives on Nasdaq Through $1 Billion Landmark Treasury Transaction
-
China's rapid solar expansion hurt bird diversity: study
US drugmaker Eli Lilly says slashing insulin prices by 70%
US pharmaceutical giant Eli Lilly announced Wednesday it was cutting the cost of its most commonly prescribed insulins by 70 percent after years of soaring prices that hit millions of Americans living with diabetes.
The announcement comes as the cost of insulin has surged in recent years, with demand increasing significantly as well.
"Lilly is taking these actions to make it easier to access Lilly insulin and help Americans who may have difficulty navigating a complex healthcare system," the Indianapolis-based drugmaker said in a statement.
The company added it would cut the price of its non-branded insulin to $25 a vial starting May 1.
It will also lower the price of Humalog, its most commonly prescribed insulin, and Humulin, by 70 percent starting in the fourth quarter of this year.
"While the current healthcare system provides access to insulin for most people with diabetes, it still does not provide affordable insulin for everyone and that needs to change," said Lilly CEO David Ricks.
The company also said Wednesday it would automatically cap out-of-pocket costs at certain retail pharmacies at $35, for people with commercial insurance using Lilly insulin.
Diabetes is one of the fastest-growing chronic diseases globally, according to a 2022 study.
- Soaring prices -
In recent decades, insulin prices have soared in the United States, costing over eight times more than in 32 comparable high-income countries, a 2020 Rand Corporation study found.
But the cost of producing insulin is relatively low compared to the sale price.
A survey by nonprofit T1International also showed that one in four respondents living with diabetes reported rationing their insulin because of the financial strain.
In his State of the Union address last month, President Joe Biden said: "Big Pharma has been unfairly charging people hundreds of dollars –- and making record profits. Not anymore."
While seniors on Medicare have the cost of insulin capped, millions of other Americans not on the federal health insurance program for the elderly need insulin to save their lives, he added.
"Let's finish the job this time. Let's cap the cost of insulin at $35 a month for every American who needs it," Biden said.
Diabetes is divided into two types. An estimated nine million people have type 1 diabetes, a chronic condition where the pancreas does not produce enough insulin -- the hormone that regulates blood sugar levels.
Most people living with diabetes have type 2, which is associated with obesity and other lifestyle factors and emerges in adults and increasingly among children.
All type 1 diabetics need insulin to survive, and generally their access is ensured.
Some 63 million people with type 2 also need the hormone, according to World Health Organization estimates, but only about half of them can access it.
V.Said--SF-PST